Comparison of COX2 expression in radiation induced basal cell carcinoma and non-radiation induced basal cell carcinoma
Authors
Abstract:
Background: Radiation-induced basal cell carcinoma (BCC) can be multiple, large, and recurring, which complicates its treatment in some cases. According to reports on the role of cyclooxygenase 2 (COX2) inhibitors in the treatment or prevention of non-melanoma skin cancers and considering the fact that COX2 expression has not been evaluated in radiation-induced basal cell carcinoma, weset out to assess the expression of COX2 in these lesions. Methods: In this study, COX2 expression was assessed by immunohistochemistry using anti-COX2 antibody on paraffinembedded blocks of 86 patients referred to Emam Reza Hospitalin Mashhad with BCC diagnosis by pathological examination (43 patients with and 43 without a history of radiotherapy) followed by semi-quantitative evaluation of COX2. Results: In our study, COX2 expression score was significantly higher in patients with a history of radiotherapy than those without radiotherapy (P<0.001). No correlation was found between theintensity and percentage of staining with sex, age, site of lesion, recurrence, and pathology of the tumor. Conclusion: Given the higher expression level of COX2 in the radiation-induced BCC patients, the use of COX2 inhibitors in these individuals may be effective in the incidence, recurrence, or treatment of BCC.
similar resources
Radiation-induced basal cell carcinoma
BACKGROUND The treatment of tinea capitis using radiotherapy was introduced at the beginning of the twentieth century. A variety of cancers including basal cell carcinoma (BCC) are seen years after this treatment. OBJECTIVE We sought to determine the clinical characteristics of BCCs among irradiated patients. METHODS The clinical records of all patients with BCC in a clinic in north of Iran...
full textProteomic Analysis of Gene Expression in Basal Cell Carcinoma
Background: Basal Cell Carcinoma (BCC) is a type of non-melanoma skin cancer. Alteration in gene expression is the important event that happens in cancer cell. Detection of this event is possible by proteomics techniques. Methods: Normal and tumor tissues were taken from BCC patient. Total proteins were purified by standard methods, and proteins were separated by two-dimensional electrophoresis...
full textBasal cell carcinoma of the lower extremities
Background: Basal cell carcinoma (BCC), the most common form of skin cancer, usually occurs in the sun-exposed areas of the body like head and neck, yet is also seen in unexpected sites. Myriad studies have mentioned a lower limb BCC incidence rate of 1.5-13.5%.Methods: The present retrospective cross-sectional study was conducted on 650 BCC patients, who were referred to the dermatology tumor ...
full textANGIOGENESIS ASSESSMENT IN BASAL CELL CARCINOMA
Basal cell carcinoma (BCC) is currently the most common cutaneous cancer found in humans. Although it generally shows a relatively benign course (BCCl), some cases show aggressive behavior (BCC2). Until recently, traditional histologic diagnostic criteria have failed to discriminate unequivocally between BCC 1 and BCC2. In this study we selected 50 cases of BCC and categorized them into tw...
full textValue of CD10 Expression in Differentiating Cutaneous Basal from Squamous Cell Carcinomas and Basal Cell Carcinoma from Trichoepithelioma
Background: In addition to the well-defined histological criteria for squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), immunohistochemical techniques can be used in difficult cases for their differentiation. As differential diagnosis between trichoepithelioma (TE) and BCC is sometimes difficult for the clinician and the pathologist, CD10 may be a useful marker for definite diagnosi...
full textThe Usefulness of CD10 in Distinguishing between Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
Background & Objectives: CD10 is a cell surface enzyme with metalloendopeptidase activity, also known as Common Acute Lymphoblastic Leukaemia Antigen, which mainly serves as a marker for acute lymphoblastic leukemia (ALL). To date and to the best of our knowledge, only few comparative immunohistochemical studies have assessed CD10 expression in cutaneous epithelial neoplasms. Our goal was to d...
full textMy Resources
Journal title
volume 22 issue 4
pages 123- 128
publication date 2019-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023